Table 3 Treatment interaction with radiomic signature and pathological stage for DMFS in patients with LARC.
From: Predicting distant metastasis and chemotherapy benefit in locally advanced rectal cancer
CT | No CT | Distant metastases-free survival | |||
---|---|---|---|---|---|
CT vs NO CT, HR (95%CI) | p | p value for interaction | |||
All (n = 629) | |||||
High RS | 176 | 103 | 1.71 (1.13–2.57) | 0.01 | 2.54 × 10−37 |
Low RS | 230 | 120 | 0.75 (0.27–2.12) | 0.59 | |
pT = 0 (n = 66) | |||||
High RS | 13 | 10 | 4.22 (0.49–36.16) | 0.15 | 0.102 |
Low RS | 24 | 19 | 1.55 (0.14–17.09) | 0.72 | |
pT = 1/2 (n = 106) | |||||
High RS | 29 | 20 | 11.66 (1.53–88.83) | 0.003 | 4.13 × 10−13 |
Low RS | 33 | 24 | NA | 0.23 | |
pT = 3/4 (n = 457) | |||||
High RS | 134 | 73 | 1.25 (0.81–1.93) | 0.32 | 5.09 × 10−29 |
Low RS | 173 | 77 | 0.76 (0.22–2.59) | 0.66 | |
pN = 0 (n = 359) | |||||
High RS | 83 | 58 | 2.67 (1.27–5.60) | 0.007 | 1.43 × 10−11 |
Low RS | 130 | 88 | 1.33 (0.24–7.26) | 0.74 | |
pN = 1 (n = 174) | |||||
High RS | 58 | 27 | 1.15 (0.57–2.30) | 0.70 | 2.76 × 10−17 |
Low RS | 68 | 21 | 0.91 (0.09–8.70) | 0.93 | |
pN = 2 (n = 96) | |||||
High RS | 35 | 18 | 1.16 (0.57–2.35) | 0.68 | 1.67 × 10−31 |
Low RS | 32 | 11 | 0.18 (0.03–1.06) | 0.03 |